Skip to Content
Search Menu

AD/PD 2026: Blood Biomarker Identifies Tau Pathology in Alzheimer's Disease

Fernando Gonzalez-Ortiz, MD, PhD, Postdoctor, University of Gothenburg, Sweden, presents in this MEDtalk from the AD/PD 2026 Conference the results of his study, which highlights phosphorylated tau at serine 262 as an MTBR-tau243 blood-based biomarker that can specifically identify tau clusters (tangles) in the brain of individuals with Alzheimer’s disease.
Fernando Gonzalez Ortiz

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Helena Sophia Gleerup

AD/PD 2026: Brain Barrier Function Shapes NfL Levels in Blood

/ Helena Sophia Gleerup
AD/PD26Alzheimer'sDementiaParkinson's Play the Video 3:27

AD/PD 2026: Visceral Adipose Tissue as a Potential Therapeutic Target in Alzheimer’s Disease

/ Jan Andreasen
AD/PD26Alzheimer's
Marja Heiskanen

AD/PD 2026: Preventing Alzheimer’s Through Early Heart Care

/ Marja Heiskanen
AD/PD26 Play the Video 02:14
Kasper Jørgensen

AD/PD 2026: Practical Clinical Tools for Differentiating Cognitive and Affective Disorders in General Practice

/ Kasper Jørgensen
AD/PD26 Play the Video 04:03
Lijun An

AD/PD 2026: AI-Driven Plasma Biomarkers for Neurodegenerative Disease

/ Lijun An
AD/PD26Parkinson's Play the Video 02:01
Frederik Bonde Jensen

AD/PD 2026: Improving Gait and Reducing Severity in Parkinson’s Disease

/ Frederik Bonde Jensen
AD/PD26Parkinson's Play the Video 02:23
César Cunha

AD/PD 2026: Genetic Risk of Alzheimer’s May Not Be Localised to the Brain

/ César Cunha
AD/PD26Alzheimer's Play the Video
Kristian Steen Frederiksen

EAN 2025: Transforming the Diagnostic Pathway in the Era of Disease-Modifying Therapies for Alzheimer’s Disease

/ Kristian Steen Frederiksen
Alzheimer'sEAN25 Play the Video 15:47

Positive Clinical Effects in the Early Stages of Alzheimer’s Disease: A Focus on Disease-Modifying Therapies

/ BestPractice Nordic
Alzheimer'sEAN24
Back to top